Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 256, Issue 8, 2018, Pages 1441-1448

  Blanc, Julie ^a   Deschasse, Clémence ^a   Kodjikian, Laurent ^b   Dot, Corinne ^c   Bron, Alain Marie ^a,d   Creuzot Garcher, Catherine ^a,d  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c HIA Desgenettes   (France)

^d CNRS   (France)

Author keywords

Dexamethasone; Intravitreal injection; Macular edema; Retinal vein occlusion

Indexed keywords

AFLIBERCEPT; DEXAMETHASONE; RANIBIZUMAB; GLUCOCORTICOID; VASCULOTROPIN A;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT EXTRACTION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; RETINA VEIN OCCLUSION; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85047918814     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-018-4016-7     Document Type: Article

References (31)

1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732. 10.1001/archopht.124.5.726
2. Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 8:1886–1894. 10.1111/j.1538-7836.2010.03909.x
3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319 e311. 10.1016/j.ophtha.2009.07.017
4. Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, Lackner K, Pfeiffer N, Mirshahi A (2015) Prevalence and risk factors of retinal vein occlusion: the Gutenberg health study. J Thromb Haemost 13:1254–1263. 10.1111/jth.12982
5. Jaulim A, Ahmed B, Khanam T, Chatziralli IP (2013) Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33:901–910. 10.1097/IAE.0b013e3182870c15
6. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G (2011) Management of retinal vein occlusion—consensus document. Ophthalmologica 226:4–28. 10.1159/000327391
7. Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D (2015) Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int 2015:870987. 10.1155/2015/870987
8. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486–491
9. Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD, Bakri SJ (2017) Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology 124:1412–1423. 10.1016/j.ophtha.2017.03.060
10. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, Group OGS (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146 e1133. 10.1016/j.ophtha.2010.03.032
11. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GSG, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460. 10.1016/j.ophtha.2011.05.014
12. SF0 Intravitreal Injection. French Society of Ophthalmology http://www.sfo.asso.fr/files/files//FICHE-INFO-PATIENT_/Fiche_65_Injection_intravitreenne_18janv16(1).pdf: Accessed 19 Feb2018
13. Korobelnik JF, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S, Velard ME (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254:2307–2318. 10.1007/s00417-016-3394-y
14. Fortoul V, Denis P, Kodjikian L (2015) Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study. Eye (Lond) 29:769–775. 10.1038/eye.2015.36
15. Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up—the SOLO study. Acta Ophthalmol 91:e340–e347. 10.1111/aos.12020
16. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A (2013) Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond) 27:65–71. 10.1038/eye.2012.226
17. Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, Group C-CS (2016) Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267. 10.1016/j.ajo.2016.04.020
18. Pommier S, Meyer F, Guigou S, Barthelemy T, Gobert F, Hajjar C, Merite PY, Parrat E, Rouhette H, Matonti F (2016) Long-term real-life efficacy and safety of repeated Ozurdex(R) injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study. Ophthalmologica 236:186–192. 10.1159/000452896
19. Danis RP, Sadda S, Jiao J, Li XY, Whitcup SM (2016) Relationship between retinal thickness and visual acuity in eyes with retinal vein occlusion treated with dexamethasone implant. Retina 36:1170–1176. 10.1097/IAE.0000000000000851
20. Noma H, Funatsu H, Mimura T, Harino S, Shimada K (2011) Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema. Retina 31:2102–2108. 10.1097/IAE.0b013e318212e24d
21. Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 34:342–351. 10.1097/IAE.0b013e318297f842
22. Bakri SJ, Omar AF, Iezzi R, Kapoor KG (2016) Evaluation of multiple dexamethasone Intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 36:552–557. 10.1097/IAE.0000000000000750
23. Chiquet C, Bron AM, Straub M, Dupuy C, Isaico R, Aptel F, Creuzot-Garcher C (2016) Retinal vein occlusions: therapeutic switch in macular oedema treatment with a 12-month follow-up. Ophthalmic Res 55:152–158. 10.1159/000442258
24. Pielen A, Buhler AD, Heinzelmann SU, Bohringer D, Ness T, Junker B (2017) Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-VEGF to dexamethasone implant and vice versa. J Ophthalmol 2017:5831682. 10.1155/2017/5831682
25. Hanhart J, Rozenman Y (2017) Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions. Ophthalmologica 238:110–118. 10.1159/000473864
26. Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G (2015) Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmic Res 53:207–216. 10.1159/000381187
27. Vie AL, Kodjikian L, Malcles A, Agard E, Voirin N, El Chehab H, Nguyen AM, Dot C (2017) Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma. Retina 37:173–178. 10.1097/IAE.0000000000001114
28. Li X, Wang N, Liang X, Xu G, Li XY, Jiao J, Lou J, Hashad Y, China Ozurdex in RVOSG (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59–69. 10.1007/s00417-017-3831-6
29. James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23:403–420. 10.1089/jop.2006.0067
30. Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478–483
31. Renfro L, Snow JS (1992) Ocular effects of topical and systemic steroids. Dermatol Clin 10:505–512